Story no.172Ongoing·Health·Low·Loire-Atlantique·26 Oct → 2 Nov·8 facts · 24 art.

In late October 2026, several cancer treatment announcements are reported: an immunotherapy extending survival in small cell lung cancer, a new family of drugs for gynecological cancers, and a personalized melanoma vaccine, with 82% of treated patients recurrence-free. On October 27, a study indicates that second-generation hormone therapy as a complement significantly prolongs survival in metastatic prostate cancer. On October 29, Professor Jean-Jacques Kiladjian highlights the gap between announcements of promising treatments and actual patient access, after the European oncology congress. In early November, reinforced immunotherapy and antibody-drug conjugate approaches against resistant tumors are mentioned, notably at the AFSOS congress, while an article revisits prostate cancer treatment by ultrasound as an alternative to surgery.